Key facts
- Bloodstream infections from treatment-resistant Klebsiella pneumoniae rose 72% between 2019 and 2025, the ECDC said.
- The ECDC puts the mortality rate for Klebsiella infections typically between 40% and 70%.
- Drug-resistant E. coli infections rose 16.4% between 2019 and 2025, against a target of a 10% cut by 2030.
- Antibiotic consumption in the EU fell 5% between 2019 and 2025, below the 20% target by 2030.
- MRSA bloodstream infections were 19% lower in 2025 than in 2019, surpassing the 15% reduction target for 2030.
- ECDC Director Pamela Rendi-Wagner said the EU is still behind on several 2030 targets to counter antimicrobial resistance.
Bloodstream infections caused by treatment-resistant Klebsiella pneumoniae in European hospitals rose 72% between 2019 and 2025, the European Centre for Disease Prevention and Control said in a bundle of reports published on November 18, 2026. The increase is far from the EU target of cutting rates by 5% by 2030.
Klebsiella infections carry a mortality rate typically between 40% and 70%, according to the ECDC, and several strains are becoming resistant to nearly all antibiotics, including new ones. Christian Giske, who leads the work at ECDC, told a press briefing that the Klebsiella findings were the biggest concern among the data collected on superbugs in Europe over the past year.
Antimicrobial resistance, the ability of bacteria and fungi to evolve resistance to drugs designed to destroy them, is estimated to kill 35,000 people in the EU, Iceland and Norway every year. Giske called it a major public health threat for Europe.
The ECDC said tackling Klebsiella requires stronger infection prevention and control in hospitals, including hand hygiene, correct use of personal protective equipment such as gloves, and effective cleaning and disinfection. Giske said Klebsiella is a gut bacterium that may have more powerful reservoirs in the body than MRSA, so measures that work for MRSA might not be sufficient.
Other targets are also unmet. Drug-resistant E. coli infections rose 16.4% between 2019 and 2025 against a goal of a 10% reduction by 2030. Antibiotic consumption in the EU fell 5% between 2019 and 2025, well below the 20% target by 2030. The share of antibiotics used in Europe that are the correct drugs as determined by the World Health Organization reached 62.5% in 2025, against a goal of at least 65%.
MRSA progress was the exception: bloodstream infections caused by drug-resistant Staphylococcus aureus were 19% lower in 2025 than in 2019, surpassing the target of a 15% reduction by 2030. ECDC Director Pamela Rendi-Wagner said in a statement that the EU is still behind on several of its 2030 targets to counter antimicrobial resistance, and cited genomic surveillance as helping authorities assess more quickly how resistant bacteria are spreading.
